Market capitalization | $67.51m |
Enterprise Value | $-4.84m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.04 |
EV/Sales (TTM) EV/Sales | -24.20 |
P/S ratio (TTM) P/S ratio | 337.55 |
P/B ratio (TTM) P/B ratio | 0.66 |
Revenue growth (TTM) Revenue growth | -76.18% |
Revenue (TTM) Revenue | $200.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:
6 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.20 0.20 |
76%
76%
|
|
Gross Profit | -2.33 -2.33 |
39%
39%
|
|
EBITDA | -117 -117 |
26%
26%
|
EBIT (Operating Income) EBIT | -119 -119 |
26%
26%
|
Net Profit | -113 -113 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Head office | United States |
CEO | Jacqueline Shea |
Employees | 122 |
Founded | 1983 |
Website | www.inovio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.